New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. IBM
5. META
6. SPY
7. ACN
8. PRIM
9. PFE
10. TSLA

Go back to New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
(NASDAQ: ROIV) Delayed: 31.53 +0.28 (0.90%)
Previous Close $31.25    52 Week High $ 
Open $31.05    52 Week Low $ 
Day High $31.74    P/E N/A 
Day Low $30.70    EPS $ 
Volume 1,749,491       

(NASDAQ: ROIV) Delayed: 31.53 +0.28 (0.90%)
Previous Close $31.25    52 Week High $ 
Open $31.05    52 Week Low $ 
Day High $31.74    P/E N/A 
Day Low $30.70    EPS $ 
Volume 1,749,491